強生創投和詹森公司在肺癌免疫療法上的合作
Aduro Expands Collaboration with Johnson & Johnson Innovation and Janssen for Lung Cancer Immunotherapies
Aduro公司擴大與強生創投公司和詹森公司在肺癌免疫療法上的合作，Aduro BioTech has entered into its second agreement with Janssen Biotech, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, granting an exclusive, worldwide license to certain product candidates engineered for the treatment of lung cancer and certain other cancers based on its novel LADD immunotherapy platform. Under the agreement, facilitated by the Johnson & Johnson Innovation center in California, Aduro will receive a $30 million up-front payment and is eligible to receive significant development, regulatory and commercialization milestone payments up to a potential total of $817 million. In addition, Aduro is eligible to receive high single-digit to double-digit tiered royalties on worldwide net sales upon successful launch and commercialization.
Audro生物科技公司與詹森強生公司的子公司，詹森生物科技公司訂立了第二份合作協議，授予後者排他性的、世界範圍內的許可，基於其創新的LADD免疫治療平臺，來生產設計用來治療肺癌和其他癌症的候選產品。根據協議，在位於加利福尼亞州的強生創新中心的協助下，Aduro公司將獲得3000萬美元的預先付款，並且能夠獲得數額巨大的研發、調整和商業化階段的付款，總額預計可達到8.17億美元。另外，Aduro有資格在藥品成功發行和商業化或，獲得全世界淨銷售額一位數或兩位數的封層辦稅提成。
Under the agreement, Janssen will have exclusive rights to develop and commercialize LADD product candidates in lung cancer and will assume responsibility for all research, development, manufacturing, regulatory and commercialization activities for the licensed products. Aduro may provide assistance in any of these areas upon request and will receive additional fees for these support activities.
根據該協議，詹森公司將擁有排他性的權利來研發和商業化治療肺癌的LADD候選產品，併爲授權產品所有的研究、發展、生產、標準和商業化承擔責任。Aduro公司可應請求在所有這些方面提供支持，並因這些幫助活動而獲得額外報酬。
"Since our initial agreement with Janssen in May of this year for new immunotherapies for prostate cancer, they have been terrific partners and we've established a strong collaboration focused on advancing our technologies forward in their licensed indications," said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro. "We believe our LADD technology also offers tremendous promise as a potential treatment for lung cancer and we are pleased to expand our relationship with Janssen, a company with significant experience and resources focused in both lung and prostate cancer. Separately, Aduro continues to make progress with our broad array of immunotherapy platforms in a number of other oncology indications, including pancreatic cancer, mesothelioma and glioblastoma among others."
自從我們在今年五月與詹森公司就新的前列腺癌免疫療法簽訂首個協議以來，他們是極好的合作伙伴，我們已經建立了強有力的合作，專注於在他們的許可適應症裏推廣我們的技術。Aduro公司的董事長、總裁和首席執行官Stephen T. Isaacs說。“我相信我們的LADD技術對於治療肺癌提供了巨大的希望，並且我們很樂意與詹森公司擴大合作，該公司專注肺癌和前列腺癌治療，擁有豐富的經驗和資源。Aduro將繼續單獨地在許多其他癌症適應症中發展我們廣泛的免疫療法平臺，包括胰腺癌、間皮瘤和其他惡性膠質瘤。The transaction is subject to clearance by the US antitrust authorities under the Hart-Scott-Rodino Act and will become final as soon as such clearance has occurred.
該交易還需要美國反壟斷局根據《斯科特•羅迪諾反壟斷改進法案》做出正式許可，並且一經許可，即刻生效。In May of this year, Aduro announced its first agreement with Janssen Biotech, Inc. granting the company an exclusive, worldwide license to certain product candidates specifically engineered for the treatment of prostate cancer based on its novel LADD immunotherapy platform. Under that agreement, also facilitated by the Johnson & Johnson Innovation center in California, Aduro is eligible to receive up to $365 million in upfront and development and commercialization milestones.
在今年5月，Aduro公司宣佈與詹森生物科技公司達成首個協議，授權該公司基於其創新的LADD免疫治療平臺，專門用於治療前列腺癌的集中候選產品的排他性的世界範圍內的生產許可。根據該協議，並藉助位於加利福尼亞州的強生創新中心，Aduro公司能夠獲得提前支付，以及研發和商業化階段總額達到3.65億美元的收入。
